Literature DB >> 30361263

Macrophage TNF-α licenses donor T cells in murine bone marrow failure and can be implicated in human aplastic anemia.

Wanling Sun1,2, Zhijie Wu1, Zenghua Lin1,3, Maile Hollinger1, Jichun Chen1, Xingmin Feng1, Neal S Young1.   

Abstract

Interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α) have been implicated historically in the immune pathophysiology of aplastic anemia (AA) and other bone marrow (BM) failure syndromes. We recently defined the essential roles of IFN-γ produced by donor T cells and the IFN-γ receptor in the host in murine immune-mediated BM failure models. TNF-α has been assumed to function similarly to IFN-γ. We used our murine models and mice genetically deficient in TNF-α or TNF-α receptors (TNF-αRs) to establish an analogous mechanism. Unexpectedly, infusion of TNF-α-/- donor lymph node (LN) cells into CByB6F1 recipients or injection of FVB LN cells into TNF-αR-/- recipients both induced BM failure, with concurrent marked increases in plasma IFN-γ and TNF-α levels. Surprisingly, in TNF-α-/- recipients, BM damage was attenuated, suggesting that TNF-α of host origin was essential for immune destruction of hematopoiesis. Depletion of host macrophages before LN injection reduced T-cell IFN-γ levels and reduced BM damage, whereas injection of recombinant TNF-α into FVB-LN cell-infused TNF-α-/- recipients increased T-cell IFN-γ expression and accelerated BM damage. Furthermore, infusion of TNF-αR-/- donor LN cells into CByB6F1 recipients reduced BM T-cell infiltration, suppressed T-cell IFN-γ production, and alleviated BM destruction. Thus, TNF-α from host macrophages and TNF-αR expressed on donor effector T cells were critical in the pathogenesis of murine immune-mediated BM failure, acting by modulation of IFN-γ secretion. In AA patients, TNF-α-producing macrophages in the BM were more frequent than in healthy controls, suggesting the involvement of this cytokine and these cells in human disease.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30361263      PMCID: PMC6307988          DOI: 10.1182/blood-2018-05-844928

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  57 in total

1.  Life-threatening reversible bone marrow toxicity in a rheumatoid arthritis patient switched from leflunomide to infliximab.

Authors:  A Marchesoni; M Arreghini; B Panni; N Battafarano; L Uziel
Journal:  Rheumatology (Oxford)       Date:  2003-01       Impact factor: 7.580

Review 2.  Current concepts in the pathophysiology and treatment of aplastic anemia.

Authors:  Neal S Young
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2013

3.  Changes in cytokine profile pre- and post-immunosuppression in acquired aplastic anemia.

Authors:  Carlo Dufour; Elisa Ferretti; Francesca Bagnasco; Oriana Burlando; Marina Lanciotti; Ugo Ramenghi; Paola Saracco; Maria Teresa Van Lint; Daniela Longoni; Giovanni Fernando Torelli; Marta Pillon; Anna Locasciulli; Aldo Misuraca; Milena La Spina; Andrea Bacigalupo; Vito Pistoia; Anna Corcione; Johanna Svahn
Journal:  Haematologica       Date:  2009-07-07       Impact factor: 9.941

4.  IFN-gamma-induced TNF-alpha expression is regulated by interferon regulatory factors 1 and 8 in mouse macrophages.

Authors:  Virginia Vila-del Sol; Carmen Punzón; Manuel Fresno
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

5.  Inhibition of JNK activation through NF-kappaB target genes.

Authors:  G Tang; Y Minemoto; B Dibling; N H Purcell; Z Li; M Karin; A Lin
Journal:  Nature       Date:  2001-11-15       Impact factor: 49.962

Review 6.  TNF receptor 2 pathway: drug target for autoimmune diseases.

Authors:  Denise Faustman; Miriam Davis
Journal:  Nat Rev Drug Discov       Date:  2010-05-21       Impact factor: 84.694

Review 7.  The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions.

Authors:  Petros P Sfikakis
Journal:  Curr Dir Autoimmun       Date:  2010-02-18

8.  Aplastic anemia following administration of a tumor necrosis factor-alpha inhibitor.

Authors:  John Kuruvilla; Heather A Leitch; Linda M Vickars; Paul F Galbraith; Charles H Li; Saad Al-Saab; Sheldon C Naiman
Journal:  Eur J Haematol       Date:  2003-11       Impact factor: 2.997

9.  Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice.

Authors:  S L Erickson; F J de Sauvage; K Kikly; K Carver-Moore; S Pitts-Meek; N Gillett; K C Sheehan; R D Schreiber; D V Goeddel; M W Moore
Journal:  Nature       Date:  1994-12-08       Impact factor: 49.962

10.  Lymphocytes with aberrant expression of Fas or Fas ligand attenuate immune bone marrow failure in a mouse model.

Authors:  Stephanie O Omokaro; Marie J Desierto; Michael A Eckhaus; Felicia M Ellison; Jichun Chen; Neal S Young
Journal:  J Immunol       Date:  2009-03-15       Impact factor: 5.422

View more
  15 in total

1.  Inhibition of 15-PGDH Protects Mice from Immune-Mediated Bone Marrow Failure.

Authors:  Julianne N P Smith; Folashade Otegbeye; Alvin P Jogasuria; Kelsey F Christo; Monika I Antczak; Joseph M Ready; Stanton L Gerson; Sanford D Markowitz; Amar B Desai
Journal:  Biol Blood Marrow Transplant       Date:  2020-05-15       Impact factor: 5.742

2.  Minimal role of interleukin 6 and toll-like receptor 2 and 4 in murine models of immune-mediated bone marrow failure.

Authors:  Sabrina Solorzano; Jisoo Kim; Jichun Chen; Xingmin Feng; Neal S Young
Journal:  PLoS One       Date:  2021-03-12       Impact factor: 3.240

3.  CCR5 maintains macrophages in the bone marrow and drives hematopoietic failure in a mouse model of severe aplastic anemia.

Authors:  Allison N Seyfried; Amanda McCabe; Julianne N P Smith; Laura M Calvi; Katherine C MacNamara
Journal:  Leukemia       Date:  2021-03-20       Impact factor: 12.883

4.  High-efficient generation of VCAM-1+ mesenchymal stem cells with multidimensional superiorities in signatures and efficacy on aplastic anaemia mice.

Authors:  Yimeng Wei; Leisheng Zhang; Ying Chi; Xiang Ren; Yuchen Gao; Baoquan Song; Chengwen Li; Zhibo Han; Lei Zhang; Zhongchao Han
Journal:  Cell Prolif       Date:  2020-06-29       Impact factor: 6.831

Review 5.  Bone Marrow Failure Syndromes, Overlapping Diseases with a Common Cytokine Signature.

Authors:  Valentina Giudice; Chiara Cardamone; Massimo Triggiani; Carmine Selleri
Journal:  Int J Mol Sci       Date:  2021-01-12       Impact factor: 5.923

6.  Prognostic value of TNF-a-308 and IFN-g-874 single nucleotide polymorphisms and their plasma levels in patients with aplastic anemia.

Authors:  Saurabh Shukla; Anil Kumar Tripathi; Shailendra Prasad Verma; Nidhi Awasthi
Journal:  Blood Res       Date:  2020-12-31

7.  Combined strategies for effective cancer immunotherapy with a novel anti-CD47 monoclonal antibody.

Authors:  Haiqing Ni; Lei Cao; Zhihai Wu; Li Wang; Shuaixiang Zhou; Xiaoli Guo; Yarong Gao; Hua Jing; Min Wu; Yang Liu; Jiazheng Ding; Pan Zhang; Ying Zhou; Bingliang Chen; Yao Xiong; Jiya Sun; Bianka Prinz; Hemanta Baruah; James Geoghegan; Michael Yu; Weiwei Wu; Junjian Liu
Journal:  Cancer Immunol Immunother       Date:  2021-06-24       Impact factor: 6.968

Review 8.  Macrophages Orchestrate Hematopoietic Programs and Regulate HSC Function During Inflammatory Stress.

Authors:  Allison N Seyfried; Jackson M Maloney; Katherine C MacNamara
Journal:  Front Immunol       Date:  2020-07-23       Impact factor: 7.561

Review 9.  Mesenchymal Stem Cells in Aplastic Anemia and Myelodysplastic Syndromes: The "Seed and Soil" Crosstalk.

Authors:  Bruno Fattizzo; Juri A Giannotta; Wilma Barcellini
Journal:  Int J Mol Sci       Date:  2020-07-30       Impact factor: 5.923

Review 10.  Aptamers and Antisense Oligonucleotides for Diagnosis and Treatment of Hematological Diseases.

Authors:  Valentina Giudice; Francesca Mensitieri; Viviana Izzo; Amelia Filippelli; Carmine Selleri
Journal:  Int J Mol Sci       Date:  2020-05-04       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.